Loading stock data…
GH Research PLC (GHRS)
$27.28-0.35 (-1.27%)
Market ClosedLast close Jul 24
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GH Research PLC in the Healthcare sector is trading at $27.28 with a market capitalization of $1.7B. Wall Street consensus targets $39.50 (8 analysts), implying a +44.8% move over the next 12 months. The stock is currently near its 52-week high of $31.00, remaining 55.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +44.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.75M↓ | -$16.70M↓ | -$16.54M↓ | -$14.69M↓ | -$12.75M |
| Net Income | -$18.97M↓ | -$14.14M↓ | -$14.02M↓ | -$9.29M↑ | -$10.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.42%
Volume
Today's trading volume
163,864
Recent News
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.
Why Psychedelic stocks are surging today
Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha
The Race to Commercialize the World’s Most Powerful Psychedelic
An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc....